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Ebola virus infection is the present public health threat that
posed the trend of worldwide pandemic [1]. At present, there is still
no effective drug and vaccine for treatment of Ebola virus
infection. An important basic knowledge for further Ebola drug
and vaccine development is the ligand system within the viral
molecule. For the Ebola virus, the study of its ligand can give
the basic require knowledge on this new virus [2]. Focusing on
the Ebola viral molecule, VP40 is mentioned as a possible drug
and vaccine target [3]. Stahelin noted that “a number of studies
have demonstrated speciﬁc deletions or mutations of VP40 to
abrogate viral egress but to date pharmacological inhibition of
VP40 has not been demonstrated [3].” To identify the ligand
within the VP40 molecule can be the clue for further speciﬁc
drug acting on VP40 search. In this study, the author hereby
determines ligand cluster and binding site within VP40 of Ebola
virus. The standard bioinformatics technique, structural
homology assessment, was used for searching [4]. According to
this study, the ligand cluster and binding site within VP35,
VP40 of Ebola virus is identiﬁed. The ligand cluster with
MAMMOTH score equal to 8.1 was identiﬁed and there were 3
identiﬁed binding sites (position 208, 216, 249) (Figure 1). The
identiﬁed ligand cluster and binding site from this preliminary
report can be used as information for further development of
antiviral drug and vaccine to combat Ebola virus infection.Acknowledgments
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